Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oritavancin - Melinta Therapeutics

Next Previous
Drug Profile

Oritavancin - Melinta Therapeutics

Alternative Names: KIMYRSA; LY-333328; LY-333328 diphosphate; Nuvocid; ORBACTIV; Oritavancin diphosphate; Ramvocid

Latest Information Update: 27 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Melinta Therapeutics; Menarini; The Medicines Company; Xediton Pharmaceuticals
  • Class Antibacterials; Glycopeptides; Peptide antibiotics
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase II Bacteraemia
  • No development reported Gram-positive infections
  • Discontinued Anthrax; Clostridium difficile infections

Most Recent Events

  • 31 Aug 2024 Preregistration for Skin and soft tissue infections in Canada (IV), in August 2024
  • 15 May 2023 Oritavancin licensed to Xediton Pharmaceuticals in Canada
  • 13 Apr 2023 Phase-II clinical trials in Skin and soft tissue infections (In adolescents, In children, In infants) in Spain, Bulgaria (IV) (EudraCT2022-001297-63)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top